ICUI — ICU Medical, Inc.

ICU Medical, Inc. Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Q4 Revenue: $536 million, reflecting a 2% organic growth but a reported decline of 14% due to the deconsolidation of the IV Solutions business.
• Full Year 2025 Revenue: 5% organic growth.
• Gross Margin: Adjusted gross margin for Q4 was 40.5%, consistent with prior guidance.
• EBITDA: $98 million for Q4, down 7% year-over-year, attributed to the deconsolidation and tariffs.
• EPS: Adjusted diluted earnings per share of $1.91, a 9% decline from $2.11 in Q4 2024.
• Free Cash Flow: $44 million for Q4, with a total of $100 million for the year.
• Debt: Ended Q4 with $1.3 billion in debt and $308 million in cash.

2. Strategic Updates and Business Highlights

• Business Segments:
  • Consumables: Grew 6% reported and 5% organic in Q4, with full-year growth of 7% reported and 6% organic. Key product lines (infusion consumables, oncology, tracheostomy) performed well.
  • IV Systems: Grew 3% reported and 1% organic in Q4, with LVPs showing low double-digit growth for the year.
  • Vital Care: Decreased 6% organically and 35% reported due to deconsolidation.
• Operational Improvements: Successful integration of Smiths Medical manufacturing sites and closure of an FDA warning letter, which may open strategic opportunities.
• Innovation: Continued focus on R&D and product development, with new FDA-clearance efforts underway for key products.

3. Forward Guidance and Outlook

• 2026 Revenue Guidance: Expected consolidated organic revenue growth in the low to mid-single-digit range, consistent with historical performance.
• Gross Margin: Projected to be around 41% for 2026, with improvements expected as integration and consolidation benefits materialize.
• Adjusted EBITDA: Forecasted range of $400 million to $430 million for 2026.
• Free Cash Flow: Anticipated to improve in 2026 due to higher earnings and reduced restructuring costs.

4. Challenges and Points of Concern

• Tariffs: Continued impact from tariffs expected to be around 2% of revenue, posing a challenge to margins.
• Deconsolidation Effects: The divestiture of the IV Solutions business has negatively impacted reported earnings and EBITDA.
• Vital Care Segment: Expected to remain flat to slightly down, indicating potential ongoing struggles in this area.
• Market Conditions: While demand appears stable, there are concerns about potential deceleration in hospital utilization volumes.

5. Notable Q&A Insights

• Customer Decision-Making: The capital environment is stable, with customers actively making decisions, but there is caution regarding competitive dynamics.
• Syringe Pump Sales: No significant slowdown in sales due to pending product clearances; customers are engaged with future product roadmaps.
• Vital Care Business: Discussions around potential divestiture are ongoing, with a focus on ensuring any transaction does not negatively impact overall earnings.
• Operational Improvements: Expected benefits from consolidation and integration efforts are anticipated to enhance free cash flow and margins moving forward.

Overall, ICU Medical reported a mixed quarter with solid operational performance in some segments but faced challenges from external factors such as tariffs and the deconsolidation of a significant business unit. The company remains focused on strategic growth and operational efficiencies as it moves into 2026.